EUVIMEDEUVIMED entdecken
Crossref

Thyroid Autoimmunity: The Treatment of Hashimoto's Disease, or the Presence of Antithyroid Antibodies Alone, in Pregnancy

Jonathan Scher, Carmen Dabao, Caitlin Rukat iD

American Journal of Reproductive Immunology · 2025

DOI: 10.1111/aji.70042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, 2025. Verfasst von Jonathan Scher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jonathan Scher MD, LLC, New York, New York, USA. Hauptthemen laut MEDLINE: Hashimoto Disease, Immunoglobulins, Intravenous, Autoantibodies, Pregnancy Complications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Problem Hashimoto's disease is the commonest autoimmune disease of pregnancy. The presence of Anti‐Thyroid antibodies (ATAs) alone [subclinical hypothyroidism] has also been shown to have adverse pregnancy effects. These can result in failure to conceive, recurrent miscarriages, anemia, preeclampsia, and abruption. Hashimoto's disease in reproduction can cause difficulty in conception through hormonal interference. It can also cause miscarriages, growth retardation, and preterm birth. The current recommended treatment is the administration of levothyroxine. This corrects the thyroid balance and may relieve the patient's hypothyroid symptoms. However, repeated recent studies have shown that it is no more effective than a placebo in correcting obstetric complications. Method of Study As a result, we decided to use an anti‐autoimmune‐directed treatment for this disorder. We selected to use IVIG for both its known powerful anti‐inflammatory and anti‐autoimmune benefits. There are several studies and observational reports in the literature on the use of IVIG in pregnancy for treating recurrent miscarriages and repeated failed IVF. However, there are no reports in the literature on using IVIG to treat Hashimoto's disease, or the presence of ATAs alone, in pregnancy.

Results

This study showed an increase in live births in the IVIG‐treated group versus the non‐IVIG‐treated group after adjustment for maternal age at delivery (OR = 4.6, 95% CI (1.1, 18.1)). There were no adverse effects in the patients who received IVIG.

Conclusion

IVIG is effective in significantly improving the obstetric outcome in patients with Hashimoto's disease, or the presence of ATAs alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hashimoto DiseaseImmunoglobulins, IntravenousAutoantibodiesPregnancy ComplicationsHumansPregnancyFemaleAdultThyroid GlandAutoimmunityPregnancy Outcome

Stichwörter der Autor:innen

Hashimoto's hypothyroidismIVIGautoimmunepregnancy loss

Substanzen

Immunoglobulins, IntravenousAutoantibodiesanti-thyroid autoantibodies

Autor:innen und Institutionen

  • Jonathan Scher MD, LLC, New York, New York, USA.
  • Placental Analytics, LLC, New Rochelle, New York, USA.

ORCID-Profile: Caitlin Rukat

Zitieren

APA

Scher, J., Dabao, C., & Rukat, C. (2025). Thyroid Autoimmunity: The Treatment of Hashimoto's Disease, or the Presence of Antithyroid Antibodies Alone, in Pregnancy. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70042

Vancouver

Scher J, Dabao C, Rukat C. Thyroid Autoimmunity: The Treatment of Hashimoto's Disease, or the Presence of Antithyroid Antibodies Alone, in Pregnancy. American Journal of Reproductive Immunology. 2025. doi:10.1111/aji.70042

BibTeX
@article{Scher2025,
  author = {Scher, Jonathan and Dabao, Carmen and Rukat, Caitlin},
  title = {Thyroid Autoimmunity: The Treatment of Hashimoto's Disease, or the Presence of Antithyroid Antibodies Alone, in Pregnancy},
  journal = {American Journal of Reproductive Immunology},
  year = {2025},
  doi = {10.1111/aji.70042}
}
Kostenlos starten →